Masayuki Nagahashi1, Junko Tsuchida2, Kazuki Moro2, Miki Hasegawa2, Kumiko Tatsuda2, Ingrid A Woelfel3, Kazuaki Takabe3, Toshifumi Wakai2. 1. Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan. Electronic address: mnagahashi@med.niigata-u.ac.jp. 2. Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan. 3. Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, Virginia.
Abstract
BACKGROUND: Sphingolipids, including sphingosine-1-phosphate (S1P) and ceramide, have emerged as key regulatory molecules that control various aspects of cell growth and proliferation in cancer. Although important roles of sphingolipids in breast cancer progression have been reported in experimental models, their roles in human patients have yet to be determined. The aims of this study were to determine the levels of sphingolipids including S1P, ceramides, and other sphingolipids, in breast cancer and normal breast tissue and to compare the difference in levels of each sphingolipid between the two tissues. MATERIALS AND METHODS: Tumor and noncancerous breast tissue were obtained from 12 patients with breast cancer. Sphingolipids including S1P, ceramides, and their metabolites of sphingosine, sphingomyelin, and monohexosylceramide were measured by liquid chromatography-electrospray ionization-tandem mass spectrometry. RESULTS: The levels of S1P, ceramides, and other sphingolipids in the tumor were significantly higher than those in normal breast tissue. There was a relatively strong correlation in the levels of S1P between the tumor and those of normal breast tissue from the same person. On the other hand, there was no correlation in the levels of most of the ceramide species between the tumor and those of normal breast tissue from the same person. CONCLUSIONS: To our knowledge, this is the first study to reveal that levels of sphingolipids in cancer tissue are generally higher than those of normal breast tissue in patients with breast cancer. The correlation of S1P levels in these tissues implicates the role of S1P in interaction between cancer and the tumor microenvironment.
BACKGROUND:Sphingolipids, including sphingosine-1-phosphate (S1P) and ceramide, have emerged as key regulatory molecules that control various aspects of cell growth and proliferation in cancer. Although important roles of sphingolipids in breast cancer progression have been reported in experimental models, their roles in humanpatients have yet to be determined. The aims of this study were to determine the levels of sphingolipids including S1P, ceramides, and other sphingolipids, in breast cancer and normal breast tissue and to compare the difference in levels of each sphingolipid between the two tissues. MATERIALS AND METHODS:Tumor and noncancerous breast tissue were obtained from 12 patients with breast cancer. Sphingolipids including S1P, ceramides, and their metabolites of sphingosine, sphingomyelin, and monohexosylceramide were measured by liquid chromatography-electrospray ionization-tandem mass spectrometry. RESULTS: The levels of S1P, ceramides, and other sphingolipids in the tumor were significantly higher than those in normal breast tissue. There was a relatively strong correlation in the levels of S1P between the tumor and those of normal breast tissue from the same person. On the other hand, there was no correlation in the levels of most of the ceramide species between the tumor and those of normal breast tissue from the same person. CONCLUSIONS: To our knowledge, this is the first study to reveal that levels of sphingolipids in cancer tissue are generally higher than those of normal breast tissue in patients with breast cancer. The correlation of S1P levels in these tissues implicates the role of S1P in interaction between cancer and the tumor microenvironment.
Authors: Kazuaki Takabe; Roger H Kim; Jeremy C Allegood; Poulami Mitra; Subramaniam Ramachandran; Masayuki Nagahashi; Kuzhuvelil B Harikumar; Nitai C Hait; Sheldon Milstien; Sarah Spiegel Journal: J Biol Chem Date: 2010-01-28 Impact factor: 5.157
Authors: Thomas D Mullen; Stefka Spassieva; Russell W Jenkins; Kazuyuki Kitatani; Jacek Bielawski; Yusuf A Hannun; Lina M Obeid Journal: J Lipid Res Date: 2010-10-11 Impact factor: 5.922
Authors: Nitai C Hait; Jeremy Allegood; Michael Maceyka; Graham M Strub; Kuzhuvelil B Harikumar; Sandeep K Singh; Cheng Luo; Ronen Marmorstein; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel Journal: Science Date: 2009-09-04 Impact factor: 47.728
Authors: Akimitsu Yamada; Masayuki Nagahashi; Tomoyoshi Aoyagi; Wei-Ching Huang; Santiago Lima; Nitai C Hait; Aparna Maiti; Kumiko Kida; Krista P Terracina; Hiroshi Miyazaki; Takashi Ishikawa; Itaru Endo; Michael R Waters; Qianya Qi; Li Yan; Sheldon Milstien; Sarah Spiegel; Kazuaki Takabe Journal: Mol Cancer Res Date: 2018-03-09 Impact factor: 5.852
Authors: Anne-Marie Lemay; Olivier Courtemanche; Timothy A Couttas; Giuleta Jamsari; Andréanne Gagné; Yohan Bossé; Philippe Joubert; Anthony S Don; David Marsolais Journal: J Lipid Res Date: 2019-08-13 Impact factor: 5.922
Authors: Eriko Katsuta; Li Yan; Masayuki Nagahashi; Ali Raza; Jamie L Sturgill; Debra E Lyon; Omar M Rashid; Nitai C Hait; Kazuaki Takabe Journal: J Surg Res Date: 2017-06-29 Impact factor: 2.192